22 news items
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
BMY
10 Jun 24
.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
. The primary endpoint of the trial is EFS. Secondary endpoints include OS, pathologic complete response and major pathologic response
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
BMY
16 May 24
, 0.9), major adverse cardiovascular events (Year 1, 0.3; Year 4, 0.3), venous thromboembolism (Year 1, 0.2; Year 4, 0.1) and deaths (Year 1, 0.2; Year
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY
15 May 24
with median duration of response not reached and the majority (77.1%) of responders in ongoing response at 18 months
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
common types of lung cancer, representing up to 84% of diagnoses. Non-metastatic cases account for the majority of NSCLC diagnoses (approximately 60
jjogelpny8p9zg7 zdfu4oieqwu7
BMY
26 Apr 24
the ureters and renal pelvis. The majority of urothelial carcinomas are diagnosed at an early stage, but approximately 50% of patients who undergo surgery
kpd6u5xvsn z4ykwiqfuvzvit2ylnmkv61fc9p5j4mab4m
BMY
25 Apr 24
Initiative to Deliver ~$1.5 Billion in Cost Savings, the Majority of Which Will be Reinvested to Fund Innovation and Drive Growth
fet3tuurjoyphvhqeb741of6m v5lhuf4zrsdacenn700bhhdtwx4vfa
AAL
AZN
BA
25 Apr 24
. “This is all in-line with our 2024 outlook that suggests the major equity indices are overvalued while the best opportunities are likely beneath
mz3inx0bans5mj d1k7ah15a0ptds0om2
BMY
15 Apr 24
Range
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between
3t76rkh
AGEN
BMY
12 Apr 24
this year and plans to present detailed Phase 2 efficacy results, including response durability and updated Phase 1 survival data, at a major medical
2qmxtm5io5e0k e8a21gguld5m64qe
BMY
JNJ
MRK
10 Apr 24
. Already present across major European markets, Mainz Biomed continues to expand the international commercialization of ColoAlert®
6s2al12ebaqofyd9jxc1a7vud31 dmu86
BMY
8 Apr 24
experienced stability or improvements in key metabolic parameters over 52 weeks of treatment.
The majority of patients (65%) experienced
03xno35rr2o3q7gb7qqbtf0piiyueej2yq3ur3n6kw gskcnszv1x42v9tx
BMY
TSVT
5 Apr 24
showed a significant improvement in overall response rates (p<0.0001) with the majority (71%) of patients treated
qp7oa395lhshizta5bs44vaksa2kxptaauv6hvt4nqd3b1mq1moz06
BMY
25 Mar 24
received ELIQUIS had a statistically significant lower risk of stroke/systemic embolism (S/SE) and major bleeding (MB) than those patients who received